Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Munire Abulimiti,Zhenyu Li,Haifeng Wang,Palida Apiziaji,Yisikandaer Abulimiti,Yao Tan
DOI: https://doi.org/10.1155/2021/9943683
IF: 4.501
2021-12-03
Journal of Oncology
Abstract:Purpose. To compare the difference in outcome of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVTT) between intensity-modulated radiotherapy (IMRT) concurrent with sorafenib and IMRT alone. Methods. A total of 82 patients with PVTT from 2014 to 2019 were included. Of these, 36 received IMRT concurrent with sorafenib treatment (group A), while 46 underwent IMRT alone (group B). The dose of IMRT was 40.0–62.5 Gy/2–2.5 Gy/4–6 w, and patients received orally administered sorafenib 400 mg twice a day in combination with IMRT. Overall survival (OS), progression-free survival (PFS), and median distant metastasis-free survival (DMFS) were evaluated by using LIFETEST procedure of SAS. Results. The median survival time was 11.0 months in group A versus 9.0 months in group B. The 1- and 2-year OS in group A were 44.9% and 3.8% versus 28.6% and 2.6% in group B ( P = 0.036 ), respectively. The median PFS was 6.0 months in group A versus 3.0 months in group B. The 1- and 2-year PFS in group A were 20.7% and 6.9% versus 2.7% and 0.0% in group B ( P = 0.012 ), respectively. The 1- and 2-year DMFS in group A were 38.0% and 7.9% versus 16.7% and 0.0% in group B ( P = 0.019 ), respectively. Multivariate analysis showed that Child–Pugh classification, AFP response, and overall response were independent risk factors for OS ( P < 0.05 ). There were no significant differences in adverse events except fatigue and skin reactions between the two groups. Conclusion. Compared with IMRT alone, IMRT concurrent with sorafenib can improve the long-term efficacy of HCC patients with PVTT, without increasing adverse reactions. The patients with Child–Pugh A, overall response, and AFP response obtained better OS.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the efficacy differences between intensity - modulated radiotherapy (IMRT) combined with sorafenib and IMRT alone in the treatment of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT). Specifically, the study aims to compare the differences between these two treatment methods in overall survival rate (OS), progression - free survival rate (PFS), and distant metastasis - free survival rate (DMFS), and at the same time explore the prognostic factors that may affect these survival indicators. ### Research Background - **HCC** is the sixth most common tumor globally, and the incidence and mortality rates in men rank second in developing countries. - The incidence rate of **PVTT** is 44.0% - 62.6%, and the median survival time is only 2.7 months because PVTT is related to complications such as intra - and extra - hepatic metastases, liver dysfunction, portal hypertension, and ascites. - Currently, treatment methods for HCC with PVTT include transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), radiotherapy, targeted therapy, or immunotherapy. Due to the possible damage to hepatocytes, the role of traditional radiotherapy in comprehensive treatment is limited. ### Research Methods - **Patient Selection**: 82 patients with HCC accompanied by PVTT were included, among which 36 patients received IMRT combined with sorafenib treatment (Group A), and 46 patients received only IMRT treatment (Group B). - **Clinical Treatment**: - **IMRT**: The total dose was 40.0 - 62.5 Gy, the fractionated dose was 2 - 2.5 Gy, and it was given 5 times a week. - **Sorafenib**: 400 mg, twice a day, simultaneously with IMRT. - **Follow - up and Evaluation**: Regular follow - up, including ECOG performance status classification, routine blood tests, biochemical tests, coagulation tests, serum alpha - fetoprotein (AFP), abdominal ultrasound, chest and abdominal CT, liver MRI, etc. ### Main Results - **Overall Survival Rate (OS)**: - The median OS in Group A was 11.0 months, and that in Group B was 9.0 months (P = 0.036). - The 1 - year and 2 - year OS were 44.9% vs 28.6% and 3.8% vs 2.6% respectively. - **Progression - Free Survival Rate (PFS)**: - The median PFS in Group A was 6.0 months, and that in Group B was 3.0 months (P = 0.012). - The 1 - year and 2 - year PFS were 20.7% vs 2.7% and 6.9% vs 0.0% respectively. - **Distant Metastasis - Free Survival Rate (DMFS)**: - The median DMFS in Group A was 10.0 months, and that in Group B was 8.0 months (P = 0.019). - The 1 - year and 2 - year DMFS were 38.0% vs 16.7% and 7.9% vs 0.0% respectively. ### Multivariate Analysis - Tongpu classification, AFP response, and overall response are independent risk factors for OS (P < 0.05). ### Safety - There were no significant differences in adverse events between the two groups, except for fatigue and skin reactions. ### Conclusion - Compared with IMRT alone, IMRT combined with sorafenib can improve the long - term efficacy in HCC patients with PVTT without increasing adverse reactions. In particular, patients with Child - Pugh grade A, good overall response, and good AFP response achieved better OS.